Antibiotic-resistant bacteria have become a rapidly growing threat to public health. Each year, they account for more than 2.8 million infections, according to the U.S. Centers for Disease Control and Prevention.
IO360: Motixafortide shows Phase II efficacy in first-line pancreatic cancer – Pharmaceutical Technology
Share this article An illustration of the human body highlighting the pancreas. Image Credit: Magic mine Pancreatic ductal adenocarcinoma (PDAC), notorious for its resistance to
March 20, 2024